



ASX ANNOUNCEMENT

RELEASE OF SHARES FROM VOLUNTARY ESCROW

SYDNEY, Monday 22 July 2013: Cellmid Limited (ASX: CDY) advises in accordance with ASX Listing Rule 3.10A that 7,500,000 ordinary shares will be released from voluntary escrow on 10 August 2013.

These shares were issued on 10 May 2013 as part consideration for the acquisition by Cellmid Limited of Advangen Inc. (Japan).

End

Contact:
Maria Halasz, CEO
T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced development programme is for the treatment of inflammatory disorders and cancer using its large portfolio of anti-midkine antibodies.

Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid is commercialising midkine as a biomarker for cancer diagnosis. The first product with midkine as one of the markers, CxBladder, was launched in the US in early 2013.

In 2010 Cellmid set up a dedicated subsidiary, Advangen International Pty Ltd, for the development of midkine for hair growth. Through this subsidiary, the Company acquired exclusive rights in certain territories to a range of hair growth products utilising FGF-5 inhibition technology. The products have since been successfully listed with the TGA and launched on the Australian pharmacy market. The Company intends to expand the distribution of these products internationally in the future.